Possible scenario
Validated AI Biology Breakthrough
40% Chance
Anthropic's wet-lab result holds up under external review, establishing Claude as a credible discovery agent for molecular biology. The enzyme system is not immediately a CRISPR replacement, but it becomes a high-profile proof point for autonomous AI-driven biotech research.
Secondary impacts
- Healthcare +1.2%
- Technology +1.1%
Tickers
- TWST+4.5%
- RXRX+3.5%
- SDGR+1.4%
Portfolio impact
S&P 500+0.6%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.